126 related articles for article (PubMed ID: 27759578)
21. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
23. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
Bellón T; Lerma V; González-Valle O; González Herrada C; de Abajo FJ
Br J Dermatol; 2016 Mar; 174(3):621-4. PubMed ID: 26412570
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
[TBL] [Abstract][Full Text] [Related]
25. A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?
Babacan T; Türkbeyler IH; Balakan O; Pehlivan Y; Suner A; Kısacık B
Int J Rheum Dis; 2017 Mar; 20(3):398-401. PubMed ID: 24815010
[TBL] [Abstract][Full Text] [Related]
26. [Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].
Sabatier-Vincent M; Charles J; Pinel N; Challende I; Claeys A; Leccia MT
Ann Dermatol Venereol; 2014 Nov; 141(11):689-93. PubMed ID: 25442474
[TBL] [Abstract][Full Text] [Related]
27. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
28. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma.
Ramani NS; Curry JL; Kapil J; Rapini RP; Tetzlaff MT; Prieto VG; Torres-Cabala CA
Am J Dermatopathol; 2015 Aug; 37(8):e96-9. PubMed ID: 25839886
[TBL] [Abstract][Full Text] [Related]
29. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
30. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
Sibaud V; Chevreau C
Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
[No Abstract] [Full Text] [Related]
31. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
[No Abstract] [Full Text] [Related]
32. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
33. Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report.
Orouji E; Ziegler B; Umansky V; Gebhardt C; Utikal J
Medicine (Baltimore); 2014 Dec; 93(28):e161. PubMed ID: 25526431
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
35. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
36. BRAF Inhibitor-Induced Panniculitis: Appearance on 18F-FDG PET/CT.
Broski SM; Moran EK; Glazebrook KN; Nathan MA
Clin Nucl Med; 2016 Mar; 41(3):e149-51. PubMed ID: 26447389
[TBL] [Abstract][Full Text] [Related]
37. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
38. Panniculitis in patients treated with BRAF inhibitors: a case series.
Choy B; Chou S; Anforth R; Fernández-Peñas P
Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511
[TBL] [Abstract][Full Text] [Related]
39. Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib.
Jhaveri KD; Sakhiya V; Fishbane S
JAMA Oncol; 2015 Nov; 1(8):1133-4. PubMed ID: 26182194
[TBL] [Abstract][Full Text] [Related]
40. Dabrafenib-associated necrobiotic granulomatous reaction.
Carlos G; Anforth R; Chou S; Fernandez-Peñas P
Australas J Dermatol; 2014 Nov; 55(4):306-8. PubMed ID: 25399793
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]